PremiumRatingsGenmab’s Promising Rina-S Developments Drive Buy Rating Amid Strong Initial Study Results Genmab’s Rina-S: Promising Efficacy and Strategic Growth Potential in Endometrial Cancer Treatment Genmab A/S Updates Articles to Enhance Capital Flexibility PremiumThe FlyGenmab price target lowered to $35 from $37 at H.C. Wainwright Genmab Executes Share Buy-back Transactions in May 2025 Genmab’s Strong Financial Performance and Promising Pipeline Justify Buy Rating PremiumThe FlyGenmab reports Q1 revenue $715M vs. $603M last year Genmab reaffirms FY25 guidance Genmab Executes Share Buy-back Transactions in Early May 2025